Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute...

Area of Science:

• Hematology
• Cancer Biology
• Epigenetics

Background:

• DNA methyltransferase 3A (DNMT3A) is frequently mutated in hematological cancers, but its oncogenic role is not fully understood.
• Mutations in DNMT3A, particularly at the Arg882 hotspot (DNMT3A(R882H)), are common in leukemia.
• Understanding the precise mechanisms by which DNMT3A mutations contribute to leukemogenesis is crucial for developing targeted therapies.

Purpose of the Study:

• To elucidate the oncogenic mechanism of DNMT3A(R882H) in cooperation with NRAS mutations in hematopoietic stem/progenitor cells.
• To investigate how DNMT3A(R882H) affects gene expression, epigenetic modifications, and leukemogenesis.
• To identify potential therapeutic strategies for DNMT3A-mutated leukemias.

Main Methods:

• Utilized a mouse model of hematopoietic stem/progenitor cell transformation and acute leukemia development.
• Employed molecular techniques to study the interaction of DNMT3A(R882H) with NRAS and its effect on stemness genes (Meis1, Mn1, Hoxa).
• Investigated epigenetic alterations, including DNA methylation and histone modifications, at cis-regulatory elements.
• Used CRISPR/Cas9 to ablate a specific enhancer element.
• Assessed the therapeutic potential of Dot1l inhibition.

Main Results:

• DNMT3A(R882H) cooperates with NRAS mutations to transform hematopoietic stem/progenitor cells and induce acute leukemia.
• DNMT3A(R882H) directly binds to and enhances the transcription of key stemness genes (Meis1, Mn1, Hoxa) essential for leukemogenicity.
• DNMT3A(R882H) causes focal epigenetic changes, including CpG hypomethylation and increased active histone marks at enhancers, promoting gene transcription.
• CRISPR/Cas9-mediated ablation of a DNMT3A(R882H)-affected enhancer reduced Meis1 expression.
• DNMT3A(R882H)-driven gene expression programs were suppressed by Dot1l inhibition.

Conclusions:

• The DNMT3A(R882H) mutation collaborates with NRAS mutations to drive acute myeloid leukemia by promoting stemness gene expression through epigenetic alterations.
• Targeting Dot1l offers a promising therapeutic avenue for patients with DNMT3A-mutated leukemias.